Immune Checkpoint Inhibitor (ICPI) induced Nephrotoxicity – An Insight.

  • Mohmad Hussian Mir Department of Medical Oncology, SKIMS, Soura
  • Tariq Ahmad Bhat Department of Medicine, SKIMS MC, Bemina
  • Khalid Parvez Sofi Department of Anesthesiology SKIMS, Soura
  • Imtiyaz Ahmad Wani Department of Nephrology, SKIMS, Soura
  • Muzafar Maqsood Wani Department of Nephrology, SKIMS, Soura
DOI: https://doi.org/10.33883/jms.v23i3.774
Keywords: immune check point inhibitors, Nephrotoxicity

Abstract

Immune check point inhibitors (ICPIs) are a new class of anti-neoplastic agents being increasingly used by oncologists to treat various malignancies. These drugs have been associated with varied side effects and have a nephrotoxic potential. Many cases of ICPI induced acute kidney injury are increasingly being reported. Their use in CKD patients on dialysis as well as in kidney transplant recipients is associated with various challenges. This review discusses the use of ICPIs in CKD, dialysis and renal transplant patients and their nephrotoxic potential  

Downloads

Download data is not yet available.

Author Biographies

Mohmad Hussian Mir, Department of Medical Oncology, SKIMS, Soura

MD. DM Assistant Professor

Tariq Ahmad Bhat, Department of Medicine, SKIMS MC, Bemina

MD, Associate Professor

Khalid Parvez Sofi, Department of Anesthesiology SKIMS, Soura

MD, Associate Professor

Imtiyaz Ahmad Wani, Department of Nephrology, SKIMS, Soura

MD, DM Professor

Muzafar Maqsood Wani, Department of Nephrology, SKIMS, Soura

MD, DM Professor

Published
2020-09-07
How to Cite
1.
Mir MH, Bhat T, Sofi KP, Wani IA, Wani MM. Immune Checkpoint Inhibitor (ICPI) induced Nephrotoxicity – An Insight. jms [Internet]. 2020Sep.7 [cited 2026Oct.2];23(3):2-. Available from: http://jmsskims.org/index.php/jms/article/view/774
Issue
Vol 23 No 3 (2020): July-Sep
Section
Review Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.